Targeted Oncology

, Volume 8, Issue 1, pp 35–45 | Cite as

Clinical meta-analyses of targeted therapies in adenocarcinoma

  • Emilio Bria
  • Maria Bonomi
  • Sara Pilotto
  • Francesco Massari
  • Silvia Novello
  • Matteo Giaj Levra
  • Giampaolo Tortora
  • Giorgio Scagliotti
Review

Abstract

Although the interpretation of the data reported in meta-analyses may hide several issues, it is undoubtable that this methodological approach may significantly contribute to implement the results of clinical trials, and represent a useful and practical tool for the evidence-based medicine process. Indeed, level-one recommendations should consider well-conducted meta-analyses as well as large and adequately powered randomized trials as the main contributors for the definition of guidelines for clinical practice. In addition, the role of meta-analyses for issues whereas conflicting data (and/or unpowered results) are provided, is well established. In the field of lung cancer, meta-analyses already participated to change the current standard, and are now facing the challenging issues of predictive biomarkers of prognosis and/or efficacy of targeted agents. With this aim, the meta-analytic approach helped in the recent years to implement the quantification of the magnitude of the benefit of targeted agents, and added new insights by interpreting the data coming from clinical trials by integrating them with biomarkers. The treatment-interaction analyses according to putative predictive factors of efficacy may clarify unknown issues and generate new hypotheses for future perspectives. The current review attempts to put in the context of the clinical data of targeted agents for lung cancer all the pros and cons of the meta-analytic process published to date, and critically analyze all the potential perspectives which this methodology may add for both current practice and forthcoming research.

Keywords

Meta-analysis Lung cancer Review Targeted agents Tyrosine kinase 

Notes

Support and Funding

This study was supported by a grant of the Italian Association for Cancer Research (AIRC-IG 11930) and from MIUR-PRIN (2009X23L78_005).

Conflicts of Interests

None of the authors have potential conflicts of interest relevant to this work.

References

  1. 1.
    National Cancer Institute: Levels of Evidence for Adult Cancer Treatment Studies, Health Professional Version. (2004). NCI Website, http://www.cancer.gov. Accessed Date Last Modified: 6/6/2003
  2. 2.
    Pignon JP, Hill C (2001) Meta-analyses of randomised clinical trials in oncology. Lancet Oncol 2(8):475–482PubMedCrossRefGoogle Scholar
  3. 3.
    Bria E, Gralla RJ, Raftopoulos H, Sperduti I, Milella M, Cognetti F, Giannarelli D Assessing two meta-analysis (MA) methods: Individual patient data-based (IPD) versus literature-based abstracted data (AD) in 10 MA including 37,002 patients (pts)—Are there differences of concern? ASCO Meeting Abstracts 29 (15_suppl):6054Google Scholar
  4. 4.
    Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group (1995). BMJ (Clinical research ed) 311 (7010):899–909Google Scholar
  5. 5.
    Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sanchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Eng J Med 361(10):958–967. doi:10.1056/NEJMoa0904554 CrossRefGoogle Scholar
  6. 6.
    Giannarelli D, Milella M, Loupakis F, Cuppone F, Vaccaro V, Sperduti I, Carlini P, Falcone A, Cognetti F, Bria E Attrition bias: Does the benefit of targeted agents (TA) increase the more we search for a selection biomarker? Meta-regression analysis of randomized clinical trials (RCTs) in advanced non-small cell lung and colorectal cancer (NSCLC/CRC). ASCO Meeting Abstracts 29 (15_suppl):6056Google Scholar
  7. 7.
    Gao G, Ren S, Li A, Xu J, Xu Q, Su C, Guo J, Deng Q, Zhou C (2012) Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from six phase III randomized controlled trials. Int J Cancer 131(5):E822–E829. doi:10.1002/ijc.27396 PubMedCrossRefGoogle Scholar
  8. 8.
    Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–957. doi:10.1056/NEJMoa0810699 PubMedCrossRefGoogle Scholar
  9. 9.
    Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, Lee JS, Yoon SJ, Han JH, Lee JW, Jo SJ (2012) First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 30(10):1122–1128. doi:10.1200/JCO.2011.36.8456 PubMedCrossRefGoogle Scholar
  10. 10.
    Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–2388. doi:10.1056/NEJMoa0909530 PubMedCrossRefGoogle Scholar
  11. 11.
    Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121–128. doi:10.1016/S1470-2045(09)70364-X PubMedCrossRefGoogle Scholar
  12. 12.
    Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, You C (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12(8):735–742. doi:10.1016/S1470-2045(11)70184-X PubMedCrossRefGoogle Scholar
  13. 13.
    Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Munoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239–246. doi:10.1016/S1470-2045(11)70393-X PubMedCrossRefGoogle Scholar
  14. 14.
    Bria E, Milella M, Cuppone F, Novello S, Ceribelli A, Vaccaro V, Sperduti I, Gelibter A, Scagliotti GV, Cognetti F, Giannarelli D (2011) Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. Annals of oncology: official journal of the European Society for Medical Oncology (ESMO) 22(10):2277–2285. doi:10.1093/annonc/mdq742 CrossRefGoogle Scholar
  15. 15.
    Ku GY, Haaland BA, De Lima LG Jr (2011) Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials. Lung cancer (Amsterdam, Netherlands) 74(3):469–473. doi:10.1016/j.lungcan.2011.04.008 CrossRefGoogle Scholar
  16. 16.
    Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1. J Clin Oncol 22(5):777–784. doi:10.1200/JCO.2004.08.001 PubMedCrossRefGoogle Scholar
  17. 17.
    Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. J Clin Oncol 22(5):785–794. doi:10.1200/JCO.2004.07.215 PubMedCrossRefGoogle Scholar
  18. 18.
    Takeda K, Hida T, Sato T, Ando M, Seto T, Satouchi M, Ichinose Y, Katakami N, Yamamoto N, Kudoh S, Sasaki J, Matsui K, Takayama K, Kashii T, Iwamoto Y, Sawa T, Okamoto I, Kurata T, Nakagawa K, Fukuoka M (2010) Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol 28(5):753–760. doi:10.1200/JCO.2009.23.3445 PubMedCrossRefGoogle Scholar
  19. 19.
    Wang F, Wang LD, Li B, Sheng ZX (2012) Gefitinib compared with systemic chemotherapy as first-line treatment for chemotherapy-naive patients with advanced non-small cell lung cancer: a meta-analysis of randomised controlled trials. Clin Oncol (R Coll Radiol) 24(6):396–401. doi:10.1016/j.clon.2011.09.013 CrossRefGoogle Scholar
  20. 20.
    Chang CH, Chen KY, Young-Xu Y, Kurth T, Orav EJ, Yang PC, Chan KA (2008) The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis. Lung cancer (Amsterdam, Netherlands) 62(2):242–252. doi:10.1016/j.lungcan.2008.03.001 CrossRefGoogle Scholar
  21. 21.
    Ibrahim EM (2010) Frontline gefitinib in advanced non-small cell lung cancer: meta-analysis of published randomized trials. Annals of thoracic medicine 5(3):153–160. doi:10.4103/1817-1737.65047 PubMedCrossRefGoogle Scholar
  22. 22.
    Jiang J, Huang L, Liang X, Zhou X, Huang R, Chu Z, Zhan Q (2011) Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Acta Oncol 50(4):582–588. doi:10.3109/0284186X.2010.546368 PubMedCrossRefGoogle Scholar
  23. 23.
    Shepherd FA, Douillard J, Fukuoka M, Saijo N, Kim S, Cufer T, Sellers MV, Armour AA, Kim ES (2009) Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): meta-analysis from four clinical trials. ASCO Meeting Abstracts 27(15S):8011Google Scholar
  24. 24.
    Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372(9652):1809–1818. doi:10.1016/S0140-6736(08)61758-4 PubMedCrossRefGoogle Scholar
  25. 25.
    Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F, Eguchi K, Takeda K, Inoue A, Tomii K, Harada M, Masuda N, Jiang H, Itoh Y, Ichinose Y, Saijo N, Fukuoka M (2008) Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 26(26):4244–4252. doi:10.1200/JCO.2007.15.0185 PubMedCrossRefGoogle Scholar
  26. 26.
    Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K (2006) Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs 17(4):401–409. doi:10.1097/01.cad.0000203381.99490.ab PubMedCrossRefGoogle Scholar
  27. 27.
    Lee DH, Park K, Kim JH, Lee JS, Shin SW, Kang JH, Ahn MJ, Ahn JS, Suh C, Kim SW (2010) Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 16(4):1307–1314. doi:10.1158/1078-0432.CCR-09-1903 PubMedCrossRefGoogle Scholar
  28. 28.
    De Marinis F, Raftopoulos H, Bria E, Gridelli C, Rossi A, Grossi F, Gralla RJ (2008) Should 3-weekly docetaxel (3WD) remain the standard for second-line therapy of advanced non-small-cell lung cancer (A-NSCLC)? Meta-analysis of 7 randomized clinical trials (RCTs) with 3WD comparator arms. ASCO Meeting Abstracts 26 (15_suppl):8087Google Scholar
  29. 29.
    Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, Esteban E, Molinier O, Brugger W, Melezinek I, Klingelschmitt G, Klughammer B, Giaccone G (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11(6):521–529. doi:10.1016/S1470-2045(10)70112-1 PubMedCrossRefGoogle Scholar
  30. 30.
    Miller VA, O’Connor P, Soh C, Kabbinavar F, for the ATLAS Investigators (2009) A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 27 (15S):LBA8002Google Scholar
  31. 31.
    Perol M, Chouaid C, Milleron BJ, Gervais R, Barlesi F, Westeel V, Crequit J, Lena H, Vergnenegre A, Perol D (2010) Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. ASCO Meeting Abstracts 28 (15_suppl):7507Google Scholar
  32. 32.
    Petrelli F, Borgonovo K, Cabiddu M, Barni S (2011) Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials. Anti-cancer drugs 22(10):1010–1019. doi:10.1097/CAD.0b013e328349d80d PubMedCrossRefGoogle Scholar
  33. 33.
    Paz-Ares L, Soulieres D, Melezinek I, Moecks J, Keil L, Mok T, Rosell R, Klughammer B (2010) Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med 14(1–2):51–69. doi:10.1111/j.1582-4934.2009.00991.x PubMedCrossRefGoogle Scholar
  34. 34.
    Dahabreh IJ, Linardou H, Siannis F, Kosmidis P, Bafaloukos D, Murray S (2010) Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 16(1):291–303. doi:10.1158/1078-0432.CCR-09-1660 CrossRefGoogle Scholar
  35. 35.
    Dahabreh IJ, Linardou H, Kosmidis P, Bafaloukos D, Murray S (2011) EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer. Annals of oncology: official journal of the European Society for Medical Oncology. ESMO 22(3):545–552. doi:10.1093/annonc/mdq432 Google Scholar
  36. 36.
    Gupta R, Dastane AM, McKenna R Jr, Marchevsky AM (2009) The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current “best evidence” with meta-analysis. Hum Pathol 40(3):356–365. doi:10.1016/j.humpath.2008.08.008 PubMedCrossRefGoogle Scholar
  37. 37.
    Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL (2009) Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. J Cancer Res Clin Oncol 135(11):1483–1493. doi:10.1007/s00432-009-0595-3 PubMedCrossRefGoogle Scholar
  38. 38.
    Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9(10):962–972. doi:10.1016/S1470-2045(08)70206-7 PubMedCrossRefGoogle Scholar
  39. 39.
    Mao C, Qiu LX, Liao RY, Du FB, Ding H, Yang WC, Li J, Chen Q (2010) KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung cancer (Amsterdam, Netherlands) 69(3):272–278. doi:10.1016/j.lungcan.2009.11.020 CrossRefGoogle Scholar
  40. 40.
    Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2):123–132. doi:10.1056/NEJMoa050753 PubMedCrossRefGoogle Scholar
  41. 41.
    Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496):1527–1537. doi:10.1016/S0140-6736(05)67625-8 PubMedCrossRefGoogle Scholar
  42. 42.
    Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23(25):5892–5899. doi:10.1200/JCO.2005.02.840 PubMedCrossRefGoogle Scholar
  43. 43.
    Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O’Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373(9674):1525–1531. doi:10.1016/S0140-6736(09)60569-9 PubMedCrossRefGoogle Scholar
  44. 44.
    Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Paschold E, Iannotti NO, Dakhil S, Gorton S, Pautret V, Weber MR, Woytowitz D (2010) Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28(6):911–917. doi:10.1200/JCO.2009.21.9618 PubMedCrossRefGoogle Scholar
  45. 45.
    Ibrahim EM, Abouelkhair KM, Al-Masri OA, Chaudry NC, Kazkaz GA (2011) Cetuximab-based therapy is effective in chemotherapy-naive patients with advanced and metastatic non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Lung 189(3):193–198. doi:10.1007/s00408-011-9286-3 PubMedCrossRefGoogle Scholar
  46. 46.
    Lin H, Jiang J, Liang X, Zhou X, Huang R (2010) Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Lung cancer (Amsterdam, Netherlands) 70(1):57–62. doi:10.1016/j.lungcan.2010.01.009 CrossRefGoogle Scholar
  47. 47.
    Butts CA, Bodkin D, Middleman EL, Englund CW, Ellison D, Alam Y, Kreisman H, Graze P, Maher J, Ross HJ, Ellis PM, McNulty W, Kaplan E, Pautret V, Weber MR, Shepherd FA (2007) Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 25(36):5777–5784. doi:10.1200/JCO.2007.13.0856 PubMedCrossRefGoogle Scholar
  48. 48.
    Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M, Mennecier BC, Pfeifer W, O’Byrne KJ, Welte T, Kolb R, Pirker R, Chemaissani A, Perol M, Ranson MR, Ellis PA, Pilz K, Reck M (2008) Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 19(2):362–369. doi:10.1093/annonc/mdm474 PubMedCrossRefGoogle Scholar
  49. 49.
    Liu L, Cao Y, Tan A, Liao C, Gao F (2010) Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials. Cancer Chemother Pharmacol 65(5):849–861. doi:10.1007/s00280-009-1090-x PubMedCrossRefGoogle Scholar
  50. 50.
    Govindan R, Bogart J, Stinchcombe T, Wang X, Hodgson L, Kratzke R, Garst J, Brotherton T, Vokes EE (2011) Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol 29(23):3120–3125. doi:10.1200/JCO.2010.33.4979 PubMedCrossRefGoogle Scholar
  51. 51.
    Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550. doi:10.1056/NEJMoa061884 PubMedCrossRefGoogle Scholar
  52. 52.
    Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27(8):1227–1234. doi:10.1200/JCO.2007.14.5466 PubMedCrossRefGoogle Scholar
  53. 53.
    Botrel TE, Clark O, Clark L, Paladini L, Faleiros E, Pegoretti B (2011) Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis. Lung cancer (Amsterdam, Netherlands) 74(1):89–97. doi:10.1016/j.lungcan.2011.01.028 CrossRefGoogle Scholar
  54. 54.
    Yang K, Wang YJ, Chen XR, Chen HN (2010) Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Clin Drug Investig 30(4):229–241. doi:10.2165/11532260-000000000-00000 PubMedCrossRefGoogle Scholar
  55. 55.
    Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22(11):2184–2191. doi:10.1200/JCO.2004.11.022 PubMedCrossRefGoogle Scholar
  56. 56.
    Nishio M, Horai T, Kunitoh H, Ichinose Y, Nishiwaki Y, Hida T, Yamamoto N, Kawahara M, Saijo N, Fukuoka M, JO19907 Study Group (2009) Randomized, open-label, multicenter phase II study of bevacizumab in combination with carboplatin and paclitaxel in chemotherapy-naive Japanese patients with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC): JO19907. ASCO Meeting Abstracts 27(15S):8036Google Scholar
  57. 57.
    Herbst RS, O’Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A (2007) Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25(30):4743–4750. doi:10.1200/JCO.2007.12.3026 PubMedCrossRefGoogle Scholar
  58. 58.
    Lima AB, Macedo LT, Sasse AD (2011) Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 6(8):e22681. doi:10.1371/journal.pone.0022681 PubMedCrossRefGoogle Scholar
  59. 59.
    Su Y, Yang WB, Li S, Ye ZJ, Shi HZ, Zhou Q (2012) Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PLoS One 7(4):e35629. doi:10.1371/journal.pone.0035629 PubMedCrossRefGoogle Scholar
  60. 60.
    Zhang X, Qin Y, Li H, Bai C, Zhu T, Xu J, Wu C, Wu M, Wang C, Song H, Wei L, He J (2011) Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Asian Pacific journal of cancer prevention: APJCP 12(11):2857–2863PubMedGoogle Scholar
  61. 61.
    Herbst RS, Sun Y, Eberhardt WE, Germonpre P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE (2010) Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 11(7):619–626. doi:10.1016/S1470-2045(10)70132-7 PubMedCrossRefGoogle Scholar
  62. 62.
    Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spasova I, Belani CP, Bodrogi I, Gadgeel S, Kennedy SJ, Hou J, Herbst RS (2007) Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 25(27):4270–4277. doi:10.1200/JCO.2006.10.5122 PubMedCrossRefGoogle Scholar
  63. 63.
    Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, Ranade AA, Cohen G, Trigo JM, Sandler AB, Bonomi PD, Herbst RS, Krebs AD, Vasselli J, Johnson BE (2008) Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26(33):5407–5415. doi:10.1200/JCO.2008.17.3138 PubMedCrossRefGoogle Scholar
  64. 64.
    de Boer RH, Arrieta O, Yang CH, Gottfried M, Chan V, Raats J, de Marinis F, Abratt RP, Wolf J, Blackhall FH, Langmuir P, Milenkova T, Read J, Vansteenkiste JF (2011) Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 29(8):1067–1074. doi:10.1200/JCO.2010.29.5717 PubMedCrossRefGoogle Scholar
  65. 65.
    Lee JS, Hirsh V, Park K, Qin S, Blajman CR, Perng RP, Chen YM, Emerson L, Langmuir P, Manegold C (2012) Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 30(10):1114–1121. doi:10.1200/JCO.2011.36.1709 PubMedCrossRefGoogle Scholar
  66. 66.
    Natale RB, Bodkin D, Govindan R, Sleckman BG, Rizvi NA, Capo A, Germonpre P, Eberhardt WE, Stockman PK, Kennedy SJ, Ranson M (2009) Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol 27(15):2523–2529. doi:10.1200/JCO.2008.18.6015 PubMedCrossRefGoogle Scholar
  67. 67.
    Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, Ferry D, Mulatero C, Whorf R, Thompson J, Barlesi F, Langmuir P, Gogov S, Rowbottom JA, Goss GD (2011) Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 29(8):1059–1066. doi:10.1200/JCO.2010.28.5981 PubMedCrossRefGoogle Scholar
  68. 68.
    Qi WX, Tang LN, He AN, Shen Z, Yao Y (2011) The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials. Lung 189(6):437–443. doi:10.1007/s00408-011-9332-1 PubMedCrossRefGoogle Scholar
  69. 69.
    Wu X, Jin Y, Cui IH, Xu Z, Zhang Y, Zhang X, Tang C, Gong Y, Chen J (2012) Addition of vandetanib to chemotherapy in advanced solid cancers: a meta-analysis. Anti-cancer drugs 23(7):731–738. doi:10.1097/CAD.0b013e32835514f4 PubMedCrossRefGoogle Scholar
  70. 70.
    Xiao YY, Zhan P, Yuan DM, Liu HB, Lv TF, Song Y, Shi Y (2012) Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. doi:10.1007/s00228-012-1333-3
  71. 71.
    Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abrao Miziara JE, Balint B, De Marinis F, Keller A, Aren O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N (2010) Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 28(11):1835–1842. doi:10.1200/JCO.2009.26.1321 PubMedCrossRefGoogle Scholar
  72. 72.
    Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, Zukin M, Walde D, Laberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, Frymire E, Gauthier I, Leighl NB, Ho C, Noble J, Lee CW, Seymour L (2010) Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 28(1):49–55. doi:10.1200/JCO.2009.22.9427 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France 2013

Authors and Affiliations

  • Emilio Bria
    • 1
  • Maria Bonomi
    • 1
  • Sara Pilotto
    • 1
  • Francesco Massari
    • 1
  • Silvia Novello
    • 2
  • Matteo Giaj Levra
    • 2
  • Giampaolo Tortora
    • 1
  • Giorgio Scagliotti
    • 2
  1. 1.Medical Oncology, Azienda Ospedaliera Universitaria Integrata (A.O.U.I.)University of VeronaVeronaItaly
  2. 2.Department of Clinical & Biological SciencesUniversity of TorinoTorinoItaly

Personalised recommendations